PubMed Health⌕ Search

PubMed · 16274329

Risperidone in pervasive developmental disorders.

Abstract

Atypical antipsychotics are increasingly used in the treatment of severe behavioral disturbances in people with pervasive developmental disorders. Among these compounds, risperidone has been the most broadly studied. This drug profile will review the available data on the use of risperidone in individuals with pervasive developmental disorders. In addition, the chemistry, pharmacokinetics, pharmacodynamics and metabolism of risperidone are discussed. Emphasis will be placed on adverse effects associated with risperidone in these people, including a discussion of measures that can be taken to monitor for these effects. Finally, a discussion of the future direction of risperidone use in this population and key issues will be presented.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Craig A Erickson, Kimberly A Stigler, David J Posey, Christopher J McDougle. 2005. Risperidone in pervasive developmental disorders.. https://doi.org/10.1586/14737175.5.6.713

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗